Cannabidiol as adjunctive therapy for drug-resistant epilepsy: a narrative review
Abstract
Background: Epilepsy is a neurological disorder characterized by recurrent seizures caused by abnormal electrical brain activity. Certain patients develop drug-resistant epilepsy, defined by the International League Against Epilepsy (ILAE) in 2017 as failure to achieve sustained seizure control despite the adequate use of at least two appropriately chosen and tolerated antiseizure medications (KWAN et al., 2010). In this context, Cannabidiol, a non-psychoactive compound derived from Cannabis sativa, has emerged as a potential adjunctive therapy (DEVINSKY et al., 2017). This study evaluates its efficacy and clinical impact. Objective: To investigate the efficacy of cannabidiol in the treatment of drug-resistant epilepsy. Compare seizure frequency between patients treated with cannabidiol and those receiving placebo. Analyze seizure frequency before and after the initiation of cannabidiol therapy. Evaluate the efficacy and safety of cannabidiol for drug-resistant epilepsy treatment. Methods: This narrative review included randomized clinical trials, observational studies, systematic reviews and meta-analyses published between 2012 and 2025 in PubMed/MEDLINE and SciELO (English and Portuguese) using the descriptors “cannabidiol”, “epilepsy”, and “drug-resistant epilepsy”. Included studies involved patients with drug-resistant epilepsy according to the 2017 International League Against Epilepsy definition, characterized by the adequate use of at least two appropriate and well-tolerated anti-seizure medications (ASMs). Experimental studies, case reports and duplicates were excluded. Results: Eleven studies met eligibility criteria: four phase III randomized controlled trials, two observational studies, and five systematic reviews with meta-analyses. Considering unique participants from primary studies, the total sample included 1,788 patients, predominantly pediatric with increasing young adult representation. Dravet syndrome and Lennox-Gastaut syndrome were most frequently studied, followed by tuberous sclerosis complex and focal epilepsies. Cannabidiol was mainly used as adjunctive therapy. Clinical trials reported median seizure reductions ranging from 40 to 50% versus placebo, while observation studies showed responder rates (≥50% reduction) up to 68.8% across different etiologies. Common adverse events included somnolence, decreased appetite, fatigue, gastrointestinal symptoms and elevated liver enzymes, particularly with concomitant valproic acid or clobazam. Higher doses were associated with increased adverse effects. Reported limitations included small samples in some analyses, methodological heterogeneity and limited follow-up. Conclusion: Adjunctive cannabidiol reduces seizures in drug-resistant epilepsy, particularly in Dravet and Lennox-Gastaut syndromes. Adverse events are mainly dose-dependent and related to concomitant antiseizure medications, supporting cannabidiol as a promising adjunctive therapeutic strategy.